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Abstract
Background: Our research focuses on the co-creation of value in healthcare with reference to a case of hereditary
angioedema with C1 inhibitor deficiency (C1-INH-HAE). Our work is mainly based on the concept of value co-creation
in healthcare. The aim of this study is to assess the impact of an alternative treatment strategy – self-administration –
by focusing on treatment outcomes and costs to understand if innovative therapeutic solutions can create value for
patients and healthcare systems.
Methods: This paper compares home-based and hospital-based therapeutic strategies (independent of treatment
type) with a cost minimization analysis. It encompasses compliance issues and focuses on both payer and societal
perspectives, also benefiting from an operationalization of the service-dominant logic model for healthcare delivery.
Data were collected over a 6-month period (August 2014–January 2015) through monthly patient interviews. Archival
data were used for variable measurement.
Results: Thirty-nine out of 62 patients enrolled in the study, experienced at least one HAE attacks, equally distributed
between home and hospital-based strategies. No evidence of correlation between therapeutic strategy and disease
severity score (p = 0.351), compliance (p = 0.399), and quality of life (p = 0.971), were found. Total direct cost per attack
amounts to € 1224 for home-based strategy with respect to € 1454 for hospital-based strategy, with a savings of € 230.
The economic advantage of the home-based strategy almost doubles if the societal perspective was considered due
to a further savings of €169 (less missed work/school days and no travel expenses).
Conclusions: Our study suggests that home-based therapies represent a feasible strategy for managing C1-INH-HAE
and may result in lower costs and increased value for both patients and the healthcare systems. The findings are
relevant to the debate on and extend the extant literature to provide a broader view of value co-creation dynamics for
home-based therapies in healthcare and their positive effects. The insights are relevant to practitioners and policy
makers.
Keywords: Value co-creation, Service-dominant logic, C1-INH-HAE, Payer perspective, Societal perspective, Compliance
Background
Economic viability, quality, and accountability are crit-
ical to health systems worldwide, considering the in-
creasing survival rates for many diseases. It is well
acknowledged that a worldwide challenge to healthcare
systems is that of rising costs, scientific, political and
economic changes, ethical issues and the demand for
greater patient safety and attention to human well-being
[1]. Factors such as the globalization, innovation and
technologic revolutions that have occurred in recent
years have triggered physicians, patients, the public and
policy makers to dedicate their attention to issues that
relate to quality of life and available treatment options.
These pressures have led European countries to intro-
duce many measures to address economic sustainability
concerns and satisfy citizens’ calls for greater account-
ability in the effectiveness and quality of health services
[2]. However, the majority of these healthcare systems
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still struggle to achieve these goals. The current focus is
no longer on survival alone but instead on “quality sur-
vival” [3], and intense debate continues on possible ways
forward.
Such an evolutionary context is characterized by the in-
creasing number of conceived interventions that attempt
to fulfill in practice the expectations of patient-centered
medicine and that have been realized at different institu-
tional levels. It is currently widely acknowledged that to
enhance the quality of healthcare service delivery – and
the quality of health systems in general – citizen involve-
ment is paramount. To enhance the quality of the health-
care services delivered, it is necessary to ensure citizen
involvement. Citizens are no longer considered mere users
of healthcare services but are highly regarded as
co-producers of the value that is created [4]. Citizens are
also considered co-producers of the increased quality
levels that the system can (or should be able to) provide
[5, 6]. Citizens, as co-producers of healthcare systems,
enable healthcare delivery processes, which are designed
according to their needs, to perform better [7, 8].
In this regard, recent contributions [9–12] enhance
and enrich the perspective of the co-creation of value
(in healthcare, too), inspired by service-dominant logic
[13, 14]. Central to these issues is the fact that conflict-
ing logic and conflicting objectives increasingly repre-
sent a central worry in healthcare, and co-creation
strategies represent a possible way forward toward a
system perspective, instead of pursuing single and sep-
arate goals to the detriment of others.
On these premises, our research focuses on the
co-creation of value in healthcare with reference to the
hereditary angioedema with a C1 inhibitor deficiency
(C1-INH-HAE). The aim of this study is to assess the im-
pact of an alternative treatment strategy –
self-administration – by focusing on treatment outcomes
and costs to assess if innovative therapeutic solutions can
create value for patients and healthcare systems.
This study compares home-based and hospital-based
therapeutic strategies (independently from the type of
treatment) with a cost minimization analysis, which re-
fers to data collected during an observational study of
adult patients at a referral center in the south of Italy
[15]. It includes an evaluation of compliance issues and
focuses on both the payer and societal perspectives. It
also benefits from an operationalization of the
service-dominant logic (SDL) model proposed by
McColl-Kennedy et al. [16] for healthcare delivery. Data
were collected over a 6-month period (August 2014–
January 2015) through monthly patient interviews with
the patients. Archival data were used for variable
measurement.
Our study suggests that home-based therapies repre-
sent a feasible strategy for managing C1-INH-HAE and
may result in cost savings and value creation for patients
and the entire health system. These findings are relevant
to debate and extend the current literature to provide a
broader view of value co-creation dynamics for
home-based therapies in healthcare and their positive ef-
fects. These insights are relevant to practitioners and
policy makers.
The remainder of the paper is organized as follows:
the second section assesses the prior literature on value
co-creation, identifying its healthcare implications, tak-
ing into account the increasing importance of SDL, and
clarifying these issues with respect to the specific case of
C1-INH-HAE. The third section describes the study
methods. The fourth reports our findings. Finally, we
discuss our results and provide some concluding
remarks.
Literature review
This section aims to provide a framework for this study
by briefly reviewing the debate concerning the increasing
relevance of value co-creation to healthcare. It highlights
several areas of primary importance to the comprehen-
sion of the phenomena investigated in general, with spe-
cial reference to C1-INH-HAE. To this end, this section
is divided into two sub-sections.
First, we clarify the conception of value that this paper
employs and the implications of a value co-creation logic
that focuses on the possible benefits to healthcare. We
systematically address multiple and conflicting objec-
tives, also showing an operational model – namely, the
service-dominant logic model – to translate such aspira-
tions into practical achievements.
We then present the extant debate on C1-INH-HAE to
highlight issues that currently affect both the literature
and practice, in turn making an argument that the in-
volvement and empowerment of patients is actually a pos-
sible way forward for value co-creation for C1-INH-HAE
management.
Value co-creation and service-dominant logic:
Implications for healthcare
As stated above, the fundamental premise of this paper
is based on the broad conception of value, which to date
is a fundamental imperative for practitioners and re-
searchers in any discipline [17]. Value is a chameleon
concept that over the last 30 years has constantly
evolved, increasingly enlarging its boundaries and con-
tent. As Gallarza et al. [17] signal, value is still nebu-
lously defined and subject to future integration. For
instance, the very early definition of value that traces
back to the 1980s was linked to the trade-off between
price and quality. In contrast, more contemporary defi-
nitions are rooted in experiential approaches that go far
beyond rationalism and encompass symbolism and
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emotions (for a deeper examination of the implications
of perceived value and its emotional dimensions, see
[18]). This is even more relevant in a field such as
healthcare, where quality of life perceptions gain mo-
mentum and are at the forefront of policy-makers’
agendas. With this in mind, the concept of value in
our study not only considers the well-acknowledged
dimensions of quality of clinical/surgical/therapeutical
procedures vs effectiveness and cost containment.
Skeptics have often characterized physicians in rela-
tion to (unclear) conceptions of value that are fea-
tured in the current debate, essentially because they
are frequently reduced to cost-reduction pressures
[19] or outcome quality demands. We therefore go
even farther to take into account dimensions relating
to patients’ emotions and feelings during medical
therapy.
The actors in the healthcare sector often have con-
flicting objectives, such as access to services, profitabil-
ity, high quality, cost containment, safety, convenience,
the centrality of the individual and patient satisfaction
[4, 20–23]. However, as briefly discussed above, the
concepts of value and quality imply more than simplis-
tic economic or financial savings but the need to reduce
expenses while preventing any negative effects on
patient care [4, 24]. Clearly, the outcomes in this
approach are multidimensional and condition specific.
They must be designed according to patient needs and
should be monitored over the entire care cycle [4, 25].
These outcomes consider the interactions of many
exogenous factors, such as compliance with recommen-
dations, complications, perceived patient satisfaction,
and clinical and patient-reported outcomes regarding
their perceived well-being [24].
In this domain, the introduction of value co-creation
logic is paramount. Such logic is driven by an awareness
that no business is an island. Value co-creation empha-
sizes processes that include actions by service providers,
customers, and possibly other actors, all-encompassing
processes with no distinction between the roles and ac-
tions of the above-cited subjects [26, 27]. This is cer-
tainly a view that fully applies to the medical field, where
cooperative practices between firms (e.g., healthcare or-
ganizations and the entire healthcare system) and cus-
tomers (e.g., physicians, patients and caregivers) can lead
to better performance overall, with the customer seen as
both a major contributor and a beneficiary [28]. Such
cooperative practices – based on dialogue and unique
one-to-one interactions (see [29]) – can be the way for-
ward to understanding these aforementioned conflicting
objectives while advancing toward the creation of value
for all of the stakeholders involved in the process.
What should be noted is that the key to achieving
such a multifaceted value is the creation of a common
goal that unifies the interests of all involved parties,
leading to circumstances in which increased patient
value (for example, perceived well-being that improves
therapeutic compliance) leads to gains for all subjects in-
volved (for instance, caregivers have a lighter caseload
and physicians reduce the risk of adverse events). Conse-
quently, the economic sustainability of the health system
is positively affected (for instance, compliance reduces
the length of the rescue time, with reductions in direct
and indirect expenditures), in turn permitting available
additional resources (in the broad sense) to be invested
in patient wellbeing (see also [4]). Recent contributions
[9–12] enhance and enrich the perspective of value
co-creation (in healthcare, too), inspired by
service-dominant logic [13, 14]. In this sense, the
traditional approach to value creation (goods-domi-
nant logic), which revolves around supply and is
based on the dichotomy between supplier and cus-
tomer, is superseded by a service-oriented approach.
The latter refers to a multitude of subjects who ac-
tively contribute to the creation of value and bring
their resources into a multidimensional co-creation
mechanism [30]. From the service-dominant perspec-
tive, the customer is not a passive subject, a mere
recipient who benefits from the value created by the
firm, but rather sits in the middle of the value cre-
ation process. The customer is able to actively create
value by carrying out his proper activities [31]. More-
over, together with him, other subjects that belong to
his service network are able to create value. Accord-
ing to SDL, the value is “in-use” rather than “in-ex-
change” [26].
Such a view may be beneficial in the healthcare setting
by increasing the efficiency of health services, improving
health outcomes (e.g., concerning compliance) at any
stage of the care cycle, reducing the cost and expend-
iture of patients, health systems, and society, and
increasing patient satisfaction [11, 32–34]. In these
cases, the co-creation process integrates the healthcare
and external resources connected to the market (e.g.,
complementary therapies and health providers/compan-
ies), to the patient’s private network (e.g., family and
friends) and to the patient himself [16, 27]. The patient
is able to use his knowledge and skills to help generate
value, a process that leads to co-production [35] and can
allow him to maximize the benefits to him and improve
his quality of life with the most appropriate conduct
(e.g., in terms of compliance with treatment [36]).
In particular, a recent piece by McColl-Kennedy et al.
[16] offers a crucial operationalization of SDL in health-
care, which is extremely useful for driving any reflections
on the field. The authors discuss several case studies that
show how the focal firm (i.e., the hospital/the research
center), the personnel involved (i.e., physicians and other
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health professionals), other market-facing sources (i.e.,
firms/other entities), public sources (i.e., support
groups, community groups and the government), pri-
vate sources (family members, colleagues and friends),
and personal sources (customers’ self-generated activ-
ities) interact to create value. In this way, these con-
stant and ever-evolving interactions may transform
the conflicting objectives between these players into
opportunities to create superior value.
Even if the need to involve patients in value co-creation
is becoming increasingly clear, the way to realize this
requires a better understanding of the concept. In this re-
gard, the debate is far from over because extant studies
have only contended that monitoring patient satisfaction
[9] and engaging patients in care-pathway design [12] are
possible viable solutions [37]. In this regard, crucial issues
that can no longer be neglected include ethical dilemmas,
the emotional involvement of patients, the need for ac-
cessible information, the essential coordinated effort
among physicians, specialist centers and patients, the pos-
session of a profound knowledge of the available alterna-
tives, and the call for accepted programs, procedures and
indicators to evaluate the quality and costs of services.
In this context, an ever-expanding debate refers to rare
diseases and their treatment to find and disseminate
solutions for improving the effective use of public re-
sources for healthcare delivery. Bearing this in mind, we
take McColl-Kennedy et al.’s concept of operationaliza-
tion [16] to deepen the issues relating to the co-creation
of value [21, 38] in the case of hereditary angioedema
with a C1 inhibitor deficiency (C1-INH-HAE). We ex-
plore the co-creation of value generated by the active in-
volvement of patients in the treatment of this rare
disease through an alternative treatment strategy:
self-administration. The aim of this study is to assess the
impact of the self-administration of plasma-derived
C1-INH (pdC1-INH) by focusing on treatment out-
comes and costs. In this way, we hope to understand if
innovative therapeutic solutions can create value for pa-
tients and the entire healthcare system.
Value co-creation in C1-INH-HAE
C1-INH-HAE is an autosomal dominant disease caused
by a quantitative (type I) or functional (type II) defi-
ciency in the C1-esterase inhibitor, which leads to the
dysregulated production of bradykinin [39, 40], a power-
ful vasodilator and a mediator of capillary leakage.
Epidemiologic data show that C1-INH-HAE affects
approximately 1 in 50,000 individuals worldwide, with
no ethnic or gender preferences [41–44]. The disease is
characterized by recurrent attacks of subcutaneous or
submucosal swelling in various body sites [39]. Abdom-
inal C1-INH-HAE episodes can be particularly debilitat-
ing and are associated with severe pain, while laryngeal
episodes can be fatal because of the risk of an airway
obstruction [39]. C1-INH-HAE afflicts patients over
their lifetime and has a very negative impact on patient
quality of life, as emphasized by a cross-sectional study
based on a patient-reported outcomes approach, in
which the health-related quality of life (HRQoL) from
the patient’s (and caregiver’s) perspective was investi-
gated [45]. These findings demonstrate the attack’s
wide-ranging impact on the patient’s life due to
short-term disability and the long-term effects caused by
anxiety and fear between attacks. Furthermore, patients
and caregivers experience an interruption in work/
school/activity during the attacks [45, 46]. The economic
burden of C1-INH-HAE is also considerably higher in
affected individuals, which is shown by a survey con-
ducted in the US from 2007 to 2008 that estimated
$42,000 in total annual costs for an average hereditary
angioedema patient [47]. Moreover, C1-INH-HAE at-
tacks are a frequent cause of ED visits [40, 48].
Due to the lack of awareness of this rare disease and
the fact that its manifestations are often indistinguish-
able from the symptoms of more common angioedema
forms, many patients do not receive timely, adequate
treatment [49]. A lack of awareness also leads to a
delayed diagnosis, as reported by an analysis of a Euro-
pean registry that found that the time between the first
swelling episode and disease diagnosis was approxi-
mately 8.5 years [50]. This delay commonly led to pro-
longed episodes, increased severity, and hospitalization
[51]. On this basis, since the publication in 2003 of the
first consensus document on hereditary angioedema
therapy [52], efforts have been made to improve the rec-
ognition and management of C1-INH-HAE. A crucial
role is played by referral centers, which provide access
to expert medical advice, patient education, and special-
ist treatment with patient-centered integrated care.
Moreover, in the last 10 years, the availability of an
effective treatment for acute attacks and appropriate
prophylaxis has contributed to the improvement of the
individual, societal and economic consequences of the
disease [46]. A recent study [53] compared the perceived
quality of life data of 134 patients and found that quality
of life significantly improved in almost all domains from
2009 to 2015. However, a significant burden of illness
remains.
In this regard, the concept of self-administration is
relevant, as it allows for the timely treatment of acute
attacks [46, 51, 54–56]. Timely intervention reduces
the duration of the attacks, reduces recovery times
and increases the quality of life of patients and care-
givers [46, 57–59]. Bygum [60] found that most
patients who learn how to perform home therapy re-
ported a significant improvement in the psychological
and physical impact of the disease. Home therapy is
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also associated with a decrease in the number of hos-
pitalizations and ED visits and a reduction in missed
work/school days for patients and caregivers [32, 57,
60–63]. Consequently, home therapy results in cost sav-
ings for both the payer and society at large [32, 62]. Des-
pite its value and the recommendations set forth by
guidelines and consensus documents [51, 54, 64–66], sev-
eral barriers to self-administration still exist, which are in-
dicated by a recent survey study designed to assess the
current practice of self-administration across Europe,
Canada and the United States [55]. These barriers de-
rive from difficulties in administration, a shortage of
nursing resources, the patients’ mental capacity, the
retaining of skills in the setting of a low attack frequency,
and the reluctance among physicians to prescribe
self-administration. The slow uptake of self-administration
has also been emphasized by guidelines and hereditary an-
gioedema expert meetings that identified training (both for
healthcare staff and patients/caregivers) and follow-up as
the key factors necessary for encouraging the uptake of this
treatment option [51, 56, 58].
This description reveals that the extant findings, al-
though incredibly important, still remain at a general
level and focus only on the shift from a hospital- to a
home-based treatment. Systematic comprehension of
issues that involve the impact of home-based strategies
compared with hospital-based strategies, such as compli-
ance with a specific therapeutic protocol, is still
under-investigated. In contrast, to comprehend whether the
involvement and empowerment of patients is actually a
possible way forward for value co-creation (that is, the sav-
ings per attack from both the payer and societal perspec-
tives, see [32, 62] in the management of C1-INH-HAE, we
also consider compliance questions to ensure a more holis-
tic approach to the phenomenon, a concept that has been
neglected to date. In addition, to fully capture the dynamics
of value creation and the impact it has on the subjects in-
volved in terms of the satisfaction of their conflicting objec-
tives, we perform an analysis that matches the payer and
societal perspectives with the SDL model put forth by
McColl-Kennedy et al. [16]. We borrow McColl-Kennedy
et al.’s categorization of the actors involved (namely, the
focal firm, other market-facing sources, public sources, pri-
vate sources and personal sources) in value co-creation in
healthcare [16] and operationalize it for C1-INH-HAE, as
reported in Fig. 1. According to this model, the payer per-
spective allows us to understand the value created for the
focal firm (i.e., the referral center) and part of the value cre-
ated for public sources (the National Health Service). On
the other hand, the societal perspective explains the
remaining value created for the public sources as well as
the value created for other market-facing sources (the drug
provider), private sources (the caregiver), and personal
sources (the patient).
Methods
This study represents a continuation and a further step
of an observational study [15], approved by Ethics Com-
mittee of Università “Federico II” (Naples, Italy), that
was conducted over a 6-month period (August 2014–
January 2015) and included type I and type II
C1-INH-HAE patients treated in a single center in Italy
(Naples). Two treatments were available: icatibant (Fira-
zyr®) administered at home by subcutaneous injection
(group 1), and pdC1-INH concentrate administered by
intravenous infusion both at home (Berinert® or Cin-
ryze®, group 2) or at hospital (only Berinert®, group 3).
For the purposes of this paper we drew from the data
collected through the above-described observational
study [15].
Regarding icatibant home-therapy, physicians teach
their patients self-administration at the time of their first
prescription. pdC1-INH concentrates are administered
by intravenous infusion. The study center started a train-
ing program funded by the drug providers (see [32]) in
2010. During the training, thanks to a simulator arm, pa-
tients also were taught how to cope with cases of laryn-
geal attack and the related impossibility of administering
the treatment. Over the period August 2014–January
2015 62 patients were in treatment at the referral center
of the current study. All of them were visited at baseline
and followed up for 6 months, recurring to phone inter-
views at least one time per month. At the beginning,
during the first dialogue, the patients were told to keep a
timely and full record of the characteristics of each at-
tack and the related treatment, as well as to take note of
any relevant features. The monthly interviews allowed us
to timely collect data, especially concerning demo-
graphic characteristics, the number of attacks in the pre-
vious month, the number of treated attacks, the number
of vials used for each attack, the number of ED visits,
and the number of missed workdays. Disease severity
was also explored relying upon the general disease sever-
ity score1 developed by Bygum et al. [67].
Results of Squeglia et al. [15] have shown no statis-
tical difference in quality of life between treatment
groups (measured using HAE-QoL questionnaire); fur-
thermore, the disease severity score was significantly
correlated with quality of life (p = 0.008), but no cor-
relation resulted between disease severity and treat-
ment strategy (p = 0.74) or compliance (p = 0.32).
Such evidences suggest to compare home-based ther-
apy (strategy 1) with hospital-based therapy (strategy
2) by employing a cost-minimization analysis, since
these different medical interventions seems to provide
the same therapeutic effects. Accordingly, patients
who did not report at least one treated attack during
the observation period (17) were excluded from the
cost-minimization analysis.
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We therefore look at cost-related differences and their
impact in terms of created value. For the abovementioned
strategies, we assessed the impact of self-administration
on the costs that relate to the management of acute
C1-INH-HAE attacks from both the Italian healthcare
payer perspective and the societal perspective.
For each of the above-mentioned groups, namely, 1)
home-based therapy with icatibant, 2) home-based ther-
apy with pdC1-INH concentrate, and 3) hospital-based
therapy with pdC1-INH concentrate (Berinert®), the first
step of the Cost-minimization analysis was to identify
the number of attacks treated with each therapeutic
strategy (strategy 1 – home-based compared with strat-
egy 2 – hospital-based). For example, for the icatibant
and pdC1-INH home-based groups, the attacks treated
at home were compiled to quantify compliance costs,
while the attacks treated at the hospital or not treated at
all were compiled to quantify non-compliance costs.
This categorization was useful to identify which types of
costs should be included in our calculations and to
consider payer and societal perspectives. From the payer
perspective, we consider only medical costs, including
drug costs and costs that involve ED visits/
hospitalization. The societal perspective encompasses
medical costs plus non-medical costs, which include
missed work/school days (for patients and caregivers)
and travel expenses for the ED visits. See Table 1 for a
summary of the computation method used.
The above-cited costs were measured as follows. Drug
costs were calculated as the number of vials multiplied
by the unitary cost of the vial. The cost of ED admission
was estimated to equal €18.59 and included only the first
evaluation. Any additional clinical examinations were
considered only when declared and according to the fees
of the Regione Campania for 2013 and the Diagnosis
Related Groups (DRGs) of the Italian National Health-
care System (see [32]). Travel expenses were calculated
on the basis of the distance reported by patients/care-
givers and the tariffs per km reported by Automobile
Club Italia [68]. The cost of missed workdays was mea-
sured according to the occupation of the patients/caregivers
and was quantified according to the net hourly wage [69].
See Table 2 for a summary of this measurement.
Finally, Quality-Adjusted Life-Years (QALYs) were
estimated by applying utility weights reported in the
HAE-BOIS-Europe survey [70] for two health states:
0.444 during an attack (the period of time before the on-
set of symptom relief ), and 0.722 following recovery
from the attack (after onset of symptom relief ), inde-
pendently of the type of therapy2, and comparable across
countries. Moreover, utility during an HAE attack is
detailed according to attack severity (0.613 for no pain
or mild, 0.467 for moderate and 0.080 for severe
attacks).
More specifically, time until resolution of treated
attacks was evaluated using the utility value 0.444,
while time between two consecutive attacks was eval-
uated using the utility value 0.722; 3 scenarios were
investigated to evaluate time until resolution of
no-treated attacks since no information about severity
were available. Scenario A: all no-treated attacks were
assumed no affecting quality of life, i.e. 0.722 utility
value was used; Scenario B: all no-treated attacks
were assumed no pain or mild, i.e. specific 0.613
Fig. 1 An operationalization of value co-creation in C1-INH-HAE
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utility value was used; Scenario C: no-treated attacks
were assumed equal to treated attacks i.e. same 0.444
utility value was used.
Consistently with previous considerations, we do not
expect differences in QALY between the two strategies
since difference in quality of life did not resulted signifi-
cant in the first analysis by Squeglia et al. [15]. However,
this calculation might be useful since QALYs allow cap-
turing the net impact of the effects of a condition.
Statistical analysis
As declared above, this analysis involves a subgroup of
patients investigated in the previous observational study,
hence the same statistical analyses were performed in
order to assess the equivalence of efficacy between
home-based and hospital strategies. The Pearson χ2 test
was used to evaluate correlation between treatment
strategy and the same clinical factors included in Sque-
glia et al. [15]: age, age at diagnosis, sex, level of educa-
tion, disease severity score, number of attacks, and the
quality of life. Furthermore, differences in quality of life,
expressed in QALYs, between home-based and hospital
strategies, were compared using the non-parametric
Wilcoxon test. Statistical analysis was performed using
IBM SPSS Statistics software, statistical significance is
defined as a p-value lower than 0.05.
Results
Out of the initial sample of 62 patients, six were lost to
follow-up and 17 report no treated attacks during the
observation period, which resulted in a final population
of 39 patients (66.6% female, mean age 33.7 years).
According to the treatment that they received, the
patients were divided into the following three groups: 20
patients were treated with home-based pdC1-INH
Table 1 Categories for computation
Payer perspective Societal perspective
Drug costs ED access/
hospitalization
Missed work days
(patient)
Missed work days
(caregiver)
Transport costs
Strategy 1 (home-based)
Compliance
costs
Always Never Quantified according to the
time of resolution declared in
the case of compliance
Only when declared by patients and
according to the time of resolution
declared in the case of compliance
Never
Non-
compliance
costs
Only in the case
of attacks treated
at the hospital
Only in the case
of attacks treated
at the hospital
Quantified according to the
time of resolution declared in
the case of non-compliance
Only when declared by patients and
according to the time of resolution
declared in the case of
non-compliance
Only in the case
of attacks treated
at the hospital
Strategy 2 (hospital-based)
Compliance
costs
Always Always Quantified according to the
time of resolution declared in
the case of compliance
Only when declared by patients and
according to the time of resolution
declared in the case of compliance
Always
Non-
compliance
costs
Never Never Quantified according to the
time of resolution declared
in the case of non-compliance
Only when declared by patients and
according to the time of resolution
declared in the case of non-compliance
Never
Table 2 Measurements
Drug costs
Commercial
name
Unitary
cost (€)
Source
Icatibant Firazyr® 1490 [72]
Plasma-derived C1 inhibitors Berinert® 557 [73]
Cinryze® 1200 [74]
ED admission/hospitalization
€ Source
First visit 18.59 [32]
Blood sample 43.09
Chest X-ray 15.49
ECG 9.97
Echo-cardio 41.32
Echo-abdomen 60.43
Missed work days
€/hour Source
Net hourly wage for the
manufacturing sector
9.62 [69]
Net hourly wage for the
construction industry
8.97
Net hourly wage for the third
sector
12.80
Net hourly wage for the service
sector
10.27
Transport costs
€/km Source
Tariff per km 0.49 [68]
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concentrate (65.0% female, mean age 33.0 years); 11
patients were treated with home-based icatibant (72.7%
female, mean age 37.0 years); and 8 patients were treated
with hospital-based pdC1-INH concentrate (62.5%
female, mean age 31.0 years). The mean severity score
was 7.8, 6.9 and 6.6 for patients who received
home-based pdC1-INH, home-based icatibant and
hospital-based pdC1-INH, respectively. The characteris-
tics of the study population and treatment groups are
summarized in Table 3.
Our analysis revealed that in the icatibant group, 188
attacks occurred over the study period, of which only 84
were treated in compliance with a home-based strategy,
requiring the consumption of 93 vials. The rest of the at-
tacks (104) were not treated at all because no ED access
was reported. In the pdC1-INH home-based group, a
total number of 556 attacks occurred over the study
period, of which 413 were treated in compliance with
the strategy, 22 were treated in the ED and the rest were
not treated at all. The consumption of vials for this
group was 765 during compliant treatment and 45 dur-
ing hospital treatment. In the pdC1-INH hospital-based
group, 54 attacks occurred over the study period, 26 of
which were treated, requiring the consumption of 67
vials. The characteristics of the attacks in these three
groups of patients are summarized in Table 4.
As expected, no statistically significant differences can
be seen between patients receiving the two strategies, with
regard to age (p = 0.182), age at diagnosis (p = 0.476), level
of education (p = 0.867), and sex (p = 0.685). Instead, there
is a correlation between the therapeutic strategy and the
number of attacks (p = 0.034), indicating that increasing
number of attacks led to opt for home-based therapy.
Consistently with the previous study [15], even in this
subpopulation there is no evidence of correlation between
therapeutic strategy and disease severity score (≥ 7 [severe
disease] or < 7 [mild to moderate disease], p = 0.351), com-
pliance (p = 0.399), and quality of life (p = 0.971).
Table 5 reports the costs of the compliant treatment
for the two considered strategies and provides details re-
garding medical and non-medical costs that focus on the
average values per patient and per attack. A first inter-
esting issue pertains to transport costs. These costs are
completely absent in strategy 1 and not relevant in strat-
egy 2. Likewise, ED access costs do not heavily impact
the strategy choice.
Compliance with strategy 1 eliminates all medical
costs except for those related to drug consumption.
However, the savings per attack (i.e., savings from the
payer perspective) were only 15.83% per attack when
comparing the two st.
rategies. Compliance with strategy 1 lowered the total
non-medical cost, with a savings of 85.9% per attack
compared with hospital-based treatment. In particular,
transport costs were completely eliminated, and missed
workday costs were lowered by 85.83%. Consequently,
the savings per attack were higher from the societal per-
spective than from the payer perspective and amounted
to 24.15%.
In addition, it is worth considering that when provid-
ing details about the payer and the societal perspectives,
these findings allow us to capture the value created for
the various players involved in these two strategies
within the SDL model. Table 6 presents the value
co-creation dynamics that occur for each strategy,
describing the objectives, the activities carried out, the
type of participation in the value-creation process, and
the value obtained.
Table 6 assumes that the objectives of each subject are
common to both strategies but can be pursued through
different routes. Starting from the patient’s initial in-
volvement, in strategy 1, all players are actively involved
in the value creation process, whereas in strategy 2, only
3 players are actively involved, and patients and care-
givers are simply recipients of the value created. The re-
sult of such a situation is a different ability to satisfy the
objectives of all actors. Strategy 2 permits only a partial
satisfaction of the objectives of the subjects involved (es-
pecially in the case of public sources and the focal firm,
for which the realization of quality outcomes in terms of
increased public health due to compliance has no effect
on cost containment) and without any systematic inter-
action. This means that we recognize different types of
value created separately and are not able to create a
superior value at a system level. In contrast, strategy 1
allows us to detect the broadest satisfaction of the
Table 3 Study population and treatment group characteristics
Home-based
pdC1-INH (N = 20)
Home-based
icatibant (N = 11)
Hospital-based pdC1-INH
(N = 8)
Overall
(N = 39)
Gender, N (%)
Female 13 (65.0) 8 (72.7) 5 (62.5) 26 (66.6)
Male 7 (35.0) 3 (27.3) 3 (37.5) 13 (33.4)
Age, mean (±SD) 33.0 (±18.7) 37.0 (±11.7) 31.0 (±20.4) 33.7 (±17.1)
Disease severity score, mean (±SD) 7.8 (±1.7) 6.9 (±1.6) 6.6 (±1.5) 7.3 (±1.7)
pdC1-INH plasma-derived C1-esterase inhibitor concentrate, SD standard deviation
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objectives and a positive interaction at the system level
that produces a superior value for all players and for the
system as a whole.
Quality of life for both home-based and hospital strat-
egies results around 0.35–0.36 QALY (Fig. 2). There is
no evidence of statistically significant differences be-
tween the two strategies in all the three scenarios (p >
0.05); furthermore QALYs are absolutely comparable in
both alternatives with an absolute difference of at most
0.005 in Scenario C. We observe that, since utility
weights range between 0 (death) and 1 (perfect health),
the maximum value of quality of life during the study
period could be 0.5 QALY; hence we can conclude that
patients living with HAE suffer a reduction in quality of
life of almost 30%.
Discussion
This study was commenced after acknowledging that
crucial concerns in healthcare come from conflicting
logics and conflicting objectives and that value
co-creation approaches represent a possible way forward
toward a system perspective, instead of pursuing single
and separate goals to the detriment of others. On this
basis, recognizing the increasing importance of rare
diseases and their impact, this study aimed to deepen
the issues relating to the co-creation of value [21, 38] in
patients with hereditary angioedema and C1 inhibitor
deficiency (C1-INH-HAE). We explored the
co-creation of value generated by the active involve-
ment of patients in the treatment of this rare disease
through an alternative treatment strategy:
self-administration. The aim of our analysis was to as-
sess the impact of the self-administration of
plasma-derived C1-INH (pdC1-INH) in terms of the
value created for all parties involved. We showed that
a home-based strategy allows us to involve all the
players in the value co-creation process, thereby pro-
ducing a superior value at the system level. Our find-
ings provide an interesting insight from many
perspectives.
First, our article adds to the extant literature on the
positive impact of self-administration and proposes a
broader interpretation of the phenomenon that is not
strictly related to the specific treatment type. This article
also considers issues related to compliance, which have
been neglected to date. Indeed, research to date has not
encompassed compliance issues and focuses only on the
specific type of treatment, thereby offering only a partial
Table 4 The number of attacks and the treatment characteristics in the three groups of patients
Number of
attacks
Number of treated attacks
(compliant and non-compliant)
% of treated attacks Number of vials Average number
of vials per attack
Strategy 1 (home-based)
Icatibant 188 84 44.68% 93 1.11
PdC1-INH 556 435 78.24% 810 1.86
Strategy 2 (hospital-based)
Hospital-based PdC1-INH 54 26 48.15% 67 2.58
Total Strategy 1 744 519 69.76% 903 1.74
Total Strategy 2 54 26 48.15% 67 2.58
pdC1-INH plasma-derived C1-esterase inhibitor concentrate
Table 5 Costs of attacks treated in compliance with the strategies
Strategy 1 (home-based) Strategy 2 (hospital-based) Savings per attack
Total Per patient
(N = 31)
Per attack
(N = 497)
Total Per patient
(N = 8)
Per attack
(N = 26)
Medical costs (€)
Drug cost 608,399.00 19,625.77 1224.14 37,319.00 4664.88 1435.35
ED visits 0 0 0 483.34 60.42 18.59
Total 608,399.00 19,625.77 1224.14 37,802.34 4725.29 1453.94
Non-medical costs (€)
Missed work/school days 13,737.47 443.14 27.64 5071.65 633.96 195.06
Travel expenses 0 0 0 39.74 4.97 1.53
Total 13,737.47 443.14 27.64 5111.39 638.92 196.59
Payer perspective (€) 608,399.00 19,625.77 1224.14 37,802.34 4725.29 1453.94 229.8
Societal perspective (€) 622,136.47 20,068.92 1251.78 42,913.73 5364.22 1650.53 398.74
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view of the value co-creation effect. More specifically, a
study conducted in Spain that compared the
self-administration of icatibant with hospital administra-
tion [62] showed an average savings of €89.8/attack from
the payer perspective and €121.30/attack from the soci-
etal perspective. In Italy, a recent observational study
assessed the treatment outcomes and costs associated
with the shift to home therapy with pdC1-INH [32].
Their results noted a significant reduction in hospitaliza-
tions and missed work/school days compared with hos-
pital drug administration and mean annual cost
decreases from €30,010.57 to 26,621.16/patient and from
€29,309.34 to 26,522.04/patient from the societal and
payer perspectives, respectively. Our analysis demon-
strates that compliance with home-based therapy elimi-
nates all medical costs except the costs of drug
consumption. Comparing the two strategies, the savings
per attack from the payer perspective amounted to
€229.8/attack, and the savings from the societal perspec-
tive amounted to €398.74/attack. Compliance with an
innovative home-based strategy is economical and af-
fordable from any point of view, but its social
Table 6 Value co-creation in C1-INH-HAE
Strategy 1 (home-based) Strategy 2 (hospital-based)
Actors Objectives Activities Partecipation
to the value
creation
process
Value obtained Activities Partecipation
to the value
creation
process
Value
obtained
Focal Cost vs
quality
Offers the therapy at
hospital
Active (increased)public health due to increased
compliance, but less medical costs per attack
other than drugs due to treatment at home
Offers the
therapy at
hospital
Active Public
health
Other
market
facing
Sales Provides the drug
and the training for
patients and
caregivers
Active (increased) profits due to increased
compliance
Provides the
drug
Active Profits
Public Cost vs
quality
Funds the focal firm Active (increased) public health due to increased
compliance, but less medical costs per attack
due to treatment at home.
(increased) social value due to less non-medical
costs per attack
Funds the
focal firm
Active Public
health
Personal Quality Involved in self-
administration
Active Value exceeding quality of care and allowing
better life and social conditions
Receives
the therapy
Recipient Care
Private Quality Involved in self-
administration
Active Value exceeding quality of care of the assisted
patient and allowing better life and social
conditions
Assists the
patient
Recipient Care of the
assisted
patient
Fig. 2 Comparison between home-based and hospital quality of life evaluated according to different assumption on no-treated attack utility.
Note. Scenario A: no-treated attack utility equals to no-attack utility; Scenario B: no-treated attack utility equals to no pain or mild attack; Scenario
C: no-treated attack utility equals to treated attack utility
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importance goes beyond the numbers. According to
our results concerning the reduction of missed work
days (missed work day costs were lowered by 85.83%
with the home-based therapy), the impact of
home-based therapy compliance not only depended
on cost reduction (+ 24.15% of savings per attack
from the societal perspective) but also involved the
outcome achieved [4]. Self-administration seems to be
a good example of value co-creation in which all of
the involved actors can benefit while the economic
sustainability of the healthcare system is considered
(see also [71], who mention the positive economic
impact of self-administration in the treatment of
hemophilia in Portugal).
Second, another interesting implication relates to the
chance that patients’ active involvement favors their
compliance with therapies. These findings even reinforce
the issues highlighted by Timmerman et al. [37] advan-
cing the importance of the involvement of users in med-
ical processes by means of innovative tools, thus
supporting the co-creation of value in healthcare. Our
findings confirm that more research on these issues
should be performed, fixing an important starting point
for new reflections in the field.
Third, our findings even reinforce the debate on SDL
and value co-creation (e.g., [9–14, 26, 30, 31]), adding
empirical substance to this theoretical model and com-
plementing it (especially for healthcare adaptations, [16])
with interesting insights rooted in the Italian healthcare
field, but expandable and adaptable to different settings.
Indeed, our findings allow us to identify the way in
which a superior value is created in a complex setting
dominated by conflicting logics, showing a possible
pathway toward avoiding a hierarchy of objectives and
moral hazard, which may result in broad systemic ad-
vantages. In this sense, self-administration unveils the
synergistic effects of the service-dominant approach in
healthcare, which enhances the role of interactions
between different value sources (the focal firm,
market-related sources, public and private sources) and
the potential of self-produced activities (personal
sources) in order to generate superior value at the sys-
tem level.
All the above contributions are not limited to the the-
oretical domain but have undeniable importance in prac-
tice, especially for policy-makers and the multiple
subjects operating in health-related fields.
Conclusions
This paper considers the economic and social impact of
two alternative therapeutic strategies. By employing a cost
minimization analysis, our study suggests a possible way
to create superior and shared value through co-creation
approaches. We conclude that home-based therapies
represent a feasible strategy for managing C1-INH-HAE
and may result in cost savings and value creation for pa-
tients as well as the entire health system. A potential limi-
tation of this study is its small sample size. However,
C1-INH-HAE is a rare disease, and the enrollment of
large patient populations is extremely difficult. Moreover,
the abovementioned savings may vary if non-compliant
treatments are introduced into our analysis. However,
given that the aim of this study was to enhance the poten-
tial of patient engagement in therapies to produce a
shared value, this option is not considered a relevant one.
On this basis, our conclusion is that although several limi-
tations still affect the employment of self-administration
in the management of acute C1-INH-HAE attacks, this
study describes a positive experience of value co-creation
in healthcare that can enhance healthcare delivery. The
value created for patients increased, and each subject
benefitted both socially and economically. Our findings
have interesting and novel implications on both the eco-
nomic and social impacts of a newer therapeutic option.
Our results also confirm the importance of patient in-
volvement in the healthcare delivery process to improve
the performance of the healthcare system as a whole.
Endnotes
1This score ranges from 0 to 10 (from the lowest to
the highest disease severity) and is based on the patient’s
age at disease onset, the number of organs ever affected,
and the need for long-term prophylaxis: age at onset 0–
5 years (3 points), age at onset 6–10 years (2 points), age
at onset, 11–20 years (1 point), age at onset > >20 years
(0 points); skin edema ever (1 point); painful abdominal
edema ever (2 points); laryngeal edema ever (2 points);
other clinical manifestations (1 point); long-term
prophylaxis (1 point).
2C1-INH concentrate occupies the same clinical pos-
ition as icatibant; there is no head-to-head clinical evi-
dence to suggest that one of these interventions is more
effective than the other, so neither is generally indicated as
a first line option (although perceptions of superiority of
one or the other may exist among clinicians). Thus, for
the treatment comparison, the clinical claim is that
C1-INH concentrate is non-inferior to icatibant in efficacy
and safety for acute HAE attacks in adults and adoles-
cents. This is based on the ASCIA management algo-
rithm, which recommends either icatibant, or C1-INH
concentrate for acute attacks. The appropriate economic
evaluation would be a cost-minimization analysis. See
both Australian and German Guidelines.
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